• Exosomal Egr2, RNF8/DAPK1, and Ischemic Stroke

  2026-08-16

  The reference study identifies a mechanistic pathway in which Egr2 carried by bone marrow mesenchymal stem cell exosomes protects OGD/R-injured neuronal cells through transcriptional activation of RNF8 and suppression of DAPK1. Its layered use of exosome characterization, promoter assays, rescue experiments, and Co-IP provides a useful framework for evaluating protein and regulatory networks, although validation remains limited to an in vitro neuronal injury model.

• Anti-Diabetic Drugs and Fracture Risk

  2026-08-15

  This systematic review and network meta-analysis integrates randomized evidence to compare fracture outcomes across anti-diabetic drug classes and individual agents in type 2 diabetes. Its main practical contribution is a more comparative safety framework: trelagliptin showed a statistically significant increase in fracture risk, whereas voglibose and albiglutide showed lower risk, while most other agents—including ertugliflozin—did not differ significantly from comparators.

• Ivermectin Workflows for Parasitology Research

  2026-08-14

  Ivermectin is a broad-spectrum anti-parasitic research compound suited to controlled dose-response, motility, viability, and host-cell selectivity workflows. This guide combines practical formulation advice with assay-design lessons from a Gasdermin C study while clearly separating established parasitology applications from exploratory cancer biology.

• Cryo-EM Reveals HCAR3 Agonist Selectivity

  2026-08-14

  Ye et al. used cryo-EM structures and cellular cAMP assays to define how HCAR3 recognizes several agonists and how its binding pocket differs from HCAR2. The study provides a structural framework for interpreting receptor selectivity and guiding lipid metabolism regulation research without relying solely on HCAR2-associated pharmacology.

• HyperScribe T7 High Yield RNA Synthesis Kit Plus

  2026-08-13

  The HyperScribe T7 High Yield RNA Synthesis Kit Plus streamlines high-output RNA production for mRNA rescue, labeled probes, and functional assays. Its scalable reaction format is especially useful for translating the FLCN mRNA rescue findings in Birt-Hogg-Dubé syndrome into reproducible bench workflows.

• ARCA EGFP mRNA (5-moUTP) Workflow Guide

  2026-08-13

  Build a reproducible fluorescence-based transfection control with capped, modified, polyadenylated mRNA rather than relying solely on plasmid DNA or indirect viability readouts. This guide covers cold-chain handling, dose-finding, mammalian-cell delivery, quantitative EGFP analysis, and storage-informed troubleshooting.

• Bile Acid Subtyping Reveals Immune Markers in CRC

  2026-08-12

  Feng et al. used transcriptomic subtyping to connect bile acid metabolism with immune features, survival, and candidate biomarkers in colorectal cancer. The study prioritizes CLCA1, UGT2A3, and ZG16 for further validation while showing why metabolic subgrouping may help interpret tumor immune heterogeneity.

• How Impending Cell Death Creates Prometastatic States

  2026-08-12

  Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending apoptotic event can enter stable prometastatic states called PAMEs. Their work links ER stress, transcriptional reprogramming, stemness, and cytokine-mediated recruitment to the emergence of a prometastatic tumor ecosystem.

• Deferoxamine mesylate: Assay Workflows

  2026-08-11

  Deferoxamine mesylate gives researchers a practical way to manipulate labile iron while probing oxidative stress, hypoxia signaling, ferroptosis, and tissue-protection phenotypes. This workflow-focused guide connects concentration selection, HIF-1α stabilization, wound healing promotion, and NRF2-linked ferroptosis biology with troubleshooting steps for reproducible assays.

• AZD0156: Translational Leverage in ATM Inhibition

  2026-08-11

  AZD0156 offers translational researchers a highly selective way to interrogate ATM-dependent DNA damage signaling, repair capacity, checkpoint control, and metabolic adaptation. This article connects mechanistic biology with experimental design, combination-strategy development, biomarker selection, and the practical realities of moving ATM inhibition toward cancer therapy research.

• Pazopanib Hydrochloride Cancer Assays

  2026-08-10

  Use Pazopanib Hydrochloride (GW786034) to separate growth arrest from cell killing in tumor, endothelial, and co-culture models. This workflow combines mechanism-aware dose design with time-resolved viability measurements for more interpretable cancer research.

• PTX3 and the TLR4/NF-κB/FGF21 Axis in ONFH

  2026-08-09

  A 2025 Communications Biology study identifies reduced pentraxin 3 (PTX3) as a mechanistic feature of glucocorticoid-induced osteonecrosis of the femoral head and defines a PTX3–TLR4/NF-κB–FGF21 signaling axis. Its combined patient, cellular, genetic, and pharmacological evidence suggests that restoring PTX3 or suppressing downstream FGF21 may help preserve osteogenesis and femoral-head architecture in preclinical models.

• LGK-974: Practical PORCN Inhibition

  2026-08-08

  LGK-974 is a nanomolar PORCN inhibitor for testing Wnt secretion, pathway activity, and Wnt-dependent tumor phenotypes with a workflow that separates target engagement from general cytotoxicity. This guide translates developmental Wnt biology into practical assay design while emphasizing dose preparation, controls, troubleshooting, and cautious extension to cancer models.

• 3-Aminobenzamide: From PARP Biology to Translation

  2026-08-07

  A translational framework for using 3-Aminobenzamide (PARP-IN-1) to connect PARP-dependent stress biology with vascular, cardiac, renal, and host–virus research—while distinguishing mechanistic evidence from therapeutic claims.

• Enhancing Apoptosis Assays with BCL-XL Inhibitor A-1155463

  2026-08-07

  This article examines how 'A-1155463' (SKU B6163), a potent and selective BCL-XL inhibitor, addresses persistent challenges in apoptosis induction, drug resistance, and tumor inhibition assays. Scenario-driven analysis demonstrates the advantages of using APExBIO's A-1155463 for reproducible, high-sensitivity research in hematological and solid tumor models.

8326 records 2/556 page Previous Next 12345 下5页 Last page